Lakefront Biotherapeutics (LKFT)

$28.02 -0.09 (-0.32%)
Market Cap 1.85B
Revenue (ttm) 1.26B
Net Income (ttm) 363.05M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 28.85%
Debt to Equity Ratio 0.00
Volume 138,600
Avg Vol 173,328
Day's Range N/A - N/A
Shares Out 65.90M
Stochastic %K 62%
Beta 0.26
Analysts Buy
Price Target $30.17

Company Profile

Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured...

Industry: Biotechnology
Sector: Healthcare
Phone: 32 1 534 29 00
Fax: 32 1 534 29 01
Address:
SchaliEnhoevedreef 20 T, Mechelen, Belgium
PickAlpha
PickAlpha Jun. 5 at 11:58 AM
4/8: Gilead and Lakefront close Ouro Medicines acquisition; GILD pays $1.675B upfront plus up to $500M milestones to add OM336 (gamgertamig) to inflammation pipeline; Lakefront earns 20%–23% royalties. $GILD $LKFT $XBI $IBB
0 · Reply
The__short_squeezer
The__short_squeezer Jun. 2 at 10:46 AM
$BB $TSLA $LKFT $TOES.X $FLNC
0 · Reply
Newsfilter
Newsfilter Oct. 3 at 8:01 PM
$LKFT Galapagos receives positive CHMP opinion for Jyseleca® European label update based on testicular function safety data from MANTA/RAy studies https://newsfilter.io/a/d2cca2a430c7ba812fe008ac13e3ea5d
0 · Reply
DummiesNixGerafft
DummiesNixGerafft Oct. 3 at 5:15 PM
@PhaseHaiko @NoGainer1 @Bohrenn @Phase0ne @macht @oooOOO000OOOooo @Hailight @Franke093 @EuerHaiko_sollteKlarSein @EuerHaiko @Hainzelkind hc mega am liefern mit $MYOV , ngc depot wenigstens unch. $LKFT geht mal so richtig ab. Experten cash wird wohl auch knapp, die nächsten kostenpflichtigen Services schon in der mache. Safe.
2 · Reply
lulz
lulz Oct. 3 at 12:03 PM
$LKFT einen Rohrkrepierer nach dem andere im NBC
1 · Reply
Bohrenn
Bohrenn Oct. 3 at 10:32 AM
$LKFT Unfassbar, was im Scamdeals No Gainer Club geboten wird. Am 11.02.2021 Bewertung Risiko 1 von 5 auf Sicht von 18 Monaten und Zielrange ca. 92€. Heute, ca. 20 Monate später, haben wir mit dieser Club-Expertise ein Investment, dass circa 40% auf den EK verloren hat und das um circa 120% steigen muss, um in die Zielrange zu gelangen. Unfassbare Verluste nur im Scamdeals No Gainer Club. >> "Wir raten Dir, gleich mit einer soliden Startposition zu beginnen."
3 · Reply
MillionTrader_xy
MillionTrader_xy Oct. 3 at 9:47 AM
$LKFT noch nichts mehr gekauft, zuerst muss der Test des ATL bestehen. Bei größeren Dip nochmal 5-10% geh ich mit hohem Gewicht rein.
0 · Reply
oliveinvest
oliveinvest Sep. 28 at 7:17 PM
Generate income with protection from volatility🛡️. Call it cushion💸. Set your cushion to whatever percentage you like. See the cushion on this fixed return outcome on $LKFT Make a fixed 5.2% (17.5% annualized) GLPG can fall 20% thru exp before you start to lose. Buy 1 $30 put Sell 2 $35 puts Exp 1/20/23 Capital Req. $3801.98 👉🏼Click my profile link to see how its done.
0 · Reply
Newsfilter
Newsfilter Sep. 27 at 9:04 PM
$LKFT Form 6-K (report of foreign issuer [rules 13a-16 and 15d-16]) filed with the SEC https://newsfilter.io/a/6b944e2cccf431854f805e0ae4ae4d14
0 · Reply
fla
fla Sep. 27 at 8:03 PM
$LKFT [15s. delayed]: Issued Press Release on September 27, 16:01:00: Galapagos increases share capital through subscription right exercis https://s.flashalert.me/7LECoa
0 · Reply
Latest News on LKFT
Galapagos Reports First Quarter 2026 Financial Results and Provides Business Update

May 6, 2026, 4:01 PM EDT - 4 weeks ago

Galapagos Reports First Quarter 2026 Financial Results and Provides Business Update

Galapagos' Shareholders Adopt All Resolutions Proposed by the Board of Directors at the Annual and Extraordinary Shareholders' Meetings 2026

Apr 28, 2026, 4:01 PM EDT - 5 weeks ago

Galapagos' Shareholders Adopt All Resolutions Proposed by the Board of Directors at the Annual and Extraordinary Shareholders' Meetings 2026

Galapagos and Gilead Enter into Binding Agreement to Collaborate on Advancing First in Class T Cell Engager Program for Autoimmune Diseases

Mar 31, 2026, 1:30 AM EDT - 2 months ago

Galapagos and Gilead Enter into Binding Agreement to Collaborate on Advancing First in Class T Cell Engager Program for Autoimmune Diseases

Galapagos Announces Nomination of Gino Santini to its Board of Directors

Mar 26, 2026, 4:02 PM EDT - 2 months ago

Galapagos Announces Nomination of Gino Santini to its Board of Directors

Galapagos Publishes 2025 Annual Report and Announces Annual and Extraordinary Shareholders' Meetings

Mar 26, 2026, 4:01 PM EDT - 2 months ago

Galapagos Publishes 2025 Annual Report and Announces Annual and Extraordinary Shareholders' Meetings

Galapagos and Gilead in Advanced Discussions to Collaborate on Advancing First in Class T Cell Engager Program for Autoimmune Diseases

Mar 23, 2026, 6:25 PM EDT - 2 months ago

Galapagos and Gilead in Advanced Discussions to Collaborate on Advancing First in Class T Cell Engager Program for Autoimmune Diseases

Galapagos Receives Transparency Notification from Bank of America

Mar 17, 2026, 5:01 PM EDT - 2 months ago

Galapagos Receives Transparency Notification from Bank of America

Galapagos Receives Transparency Notifications from Bank of America

Mar 10, 2026, 5:01 PM EDT - 3 months ago

Galapagos Receives Transparency Notifications from Bank of America

Galapagos Creates New Subscription Right Plan

Mar 6, 2026, 4:01 PM EST - 3 months ago

Galapagos Creates New Subscription Right Plan

Galapagos Appoints Tania Philipp as Chief Human Resources Officer

Mar 5, 2026, 4:01 PM EST - 3 months ago

Galapagos Appoints Tania Philipp as Chief Human Resources Officer

Galapagos Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update

Feb 23, 2026, 4:01 PM EST - 3 months ago

Galapagos Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update

Galapagos Announces Board Decision to Initiate Wind-Down of Cell Therapy Activities

Jan 5, 2026, 4:01 PM EST - 5 months ago

Galapagos Announces Board Decision to Initiate Wind-Down of Cell Therapy Activities

Galapagos Presented New ATALANTA-1 Cell Therapy Data in MCL at ASH 2025

Dec 8, 2025, 1:30 AM EST - 6 months ago

Galapagos Presented New ATALANTA-1 Cell Therapy Data in MCL at ASH 2025

Galapagos to Present New Data from Cell Therapy Program at ASH 2025

Nov 3, 2025, 4:01 PM EST - 7 months ago

Galapagos to Present New Data from Cell Therapy Program at ASH 2025

Galapagos to Present In Vitro Data at ACR Convergence 2025 Suggesting Differentiation of GLPG3667 from Other TYK2 Inhibitors

Oct 23, 2025, 4:01 PM EDT - 8 months ago

Galapagos to Present In Vitro Data at ACR Convergence 2025 Suggesting Differentiation of GLPG3667 from Other TYK2 Inhibitors

Biotech firm Galapagos to wind down cell therapy business

Oct 21, 2025, 3:34 AM EDT - 8 months ago

Biotech firm Galapagos to wind down cell therapy business

Galapagos Announces Intention to Wind Down Cell Therapy Business as Part of the Company's Ongoing Transformation

Oct 21, 2025, 1:30 AM EDT - 8 months ago

Galapagos Announces Intention to Wind Down Cell Therapy Business as Part of the Company's Ongoing Transformation

Galapagos Announces Appointment of Fred Blakeslee as General Counsel

Oct 16, 2025, 4:01 PM EDT - 8 months ago

Galapagos Announces Appointment of Fred Blakeslee as General Counsel

Biotechnology firm Galapagos receives offers for cell-therapy business

Oct 1, 2025, 4:12 PM EDT - 8 months ago

Biotechnology firm Galapagos receives offers for cell-therapy business

Galapagos Provides Update on Strategic Alternatives for Its Cell Therapy Business

Oct 1, 2025, 4:01 PM EDT - 8 months ago

Galapagos Provides Update on Strategic Alternatives for Its Cell Therapy Business

Galapagos NV Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to GLPG5101 for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma

Aug 6, 2025, 1:30 AM EDT - 10 months ago

Galapagos NV Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to GLPG5101 for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma

Galapagos Bolster Leadership Team with Seasoned Life Sciences Executives to Accelerate Business Transformation

Jul 23, 2025, 4:03 PM EDT - 11 months ago

Galapagos Bolster Leadership Team with Seasoned Life Sciences Executives to Accelerate Business Transformation

Galapagos Welcomes Seasoned Pharmaceutical Executives Dawn Svoronos and Jane Griffiths to Its Board of Directors

Jul 23, 2025, 4:02 PM EDT - 11 months ago

Galapagos Welcomes Seasoned Pharmaceutical Executives Dawn Svoronos and Jane Griffiths to Its Board of Directors

Galapagos Reports Half-Year 2025 Financial Results and Provides Second Quarter Business Update

Jul 23, 2025, 4:01 PM EDT - 11 months ago

Galapagos Reports Half-Year 2025 Financial Results and Provides Second Quarter Business Update

Galapagos Appoints Aaron Cox as Chief Financial Officer

Jun 23, 2025, 1:30 AM EDT - 1 year ago

Galapagos Appoints Aaron Cox as Chief Financial Officer

Galapagos Presented New Data at ICML 2025 From Cohort 3 of ATALANTA-1 in Relapsed/Refractory Indolent NHL Patients, Demonstrating High Complete Response and MRD Negativity Rates With CAR-T Candidate GLPG5101

Jun 18, 2025, 4:01 PM EDT - 1 year ago

Galapagos Presented New Data at ICML 2025 From Cohort 3 of ATALANTA-1 in Relapsed/Refractory Indolent NHL Patients, Demonstrating High Complete Response and MRD Negativity Rates With CAR-T Candidate GLPG5101

Galapagos to Present New ATALANTA-1 CAR-T Data at EHA 2025, Highlighting Low Toxicity and Rapid, Decentralized Delivery of Fresh, Early-Memory-Enriched GLPG5101 in R/R NHL

Jun 12, 2025, 4:01 PM EDT - 1 year ago

Galapagos to Present New ATALANTA-1 CAR-T Data at EHA 2025, Highlighting Low Toxicity and Rapid, Decentralized Delivery of Fresh, Early-Memory-Enriched GLPG5101 in R/R NHL

Galapagos Announces Strategic Update on Proposed Separation, Executive Leadership Transition and Board Changes

May 13, 2025, 1:36 AM EDT - 1 year ago

Galapagos Announces Strategic Update on Proposed Separation, Executive Leadership Transition and Board Changes

Galapagos Reports First Quarter 2025 Financial Results, Recent Business Highlights and Near-Term Catalysts

Apr 23, 2025, 4:01 PM EDT - 1 year ago

Galapagos Reports First Quarter 2025 Financial Results, Recent Business Highlights and Near-Term Catalysts

Galapagos Announces Departure of Thad Huston, CFO and COO, as of August 1, 2025

Apr 15, 2025, 1:30 AM EDT - 1 year ago

Galapagos Announces Departure of Thad Huston, CFO and COO, as of August 1, 2025

Galapagos Publishes 2024 Annual Report and Announces Annual Shareholders' Meeting

Mar 27, 2025, 4:01 PM EDT - 1 year ago

Galapagos Publishes 2024 Annual Report and Announces Annual Shareholders' Meeting

Galapagos to Present at Upcoming Investor Conferences

Feb 24, 2025, 4:01 PM EST - 1 year ago

Galapagos to Present at Upcoming Investor Conferences

Galapagos receives transparency notification and 13D filing from Tang Capital

Feb 17, 2025, 4:01 PM EST - 1 year ago

Galapagos receives transparency notification and 13D filing from Tang Capital

Galapagos Reports Full Year 2024 Results and Provides Fourth Quarter Business Update

Feb 12, 2025, 4:01 PM EST - 1 year ago

Galapagos Reports Full Year 2024 Results and Provides Fourth Quarter Business Update

Galapagos To Spin Off Innovative Medicines Business

Jan 21, 2025, 12:08 PM EST - 1 year ago

Galapagos To Spin Off Innovative Medicines Business

Galapagos to Unlock Shareholder Value by Declaring its Intent to Separate into Two Publicly Traded Entities

Jan 8, 2025, 1:30 AM EST - 1 year ago

Galapagos to Unlock Shareholder Value by Declaring its Intent to Separate into Two Publicly Traded Entities

Galapagos to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 7, 2025, 4:01 PM EST - 1 year ago

Galapagos to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Galapagos Announces Encouraging New Results from Ongoing Phase 1/2 Study of CD19 CAR T-Cell Therapy, GLPG5101, in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

Dec 7, 2024, 12:30 PM EST - 1 year ago

Galapagos Announces Encouraging New Results from Ongoing Phase 1/2 Study of CD19 CAR T-Cell Therapy, GLPG5101, in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

Galapagos to Present Results of Pioneering Innovation in Cancer Cell Therapy at ASH 2024

Nov 5, 2024, 4:01 PM EST - 1 year ago

Galapagos to Present Results of Pioneering Innovation in Cancer Cell Therapy at ASH 2024

Galapagos Reports Third Quarter 2024 Financial Results and Provides Business Update

Oct 30, 2024, 4:01 PM EDT - 1 year ago

Galapagos Reports Third Quarter 2024 Financial Results and Provides Business Update

Galapagos welcomes Oleg Nodelman to its Board of Directors to support strategic growth

Oct 7, 2024, 1:00 AM EDT - 1 year ago

Galapagos welcomes Oleg Nodelman to its Board of Directors to support strategic growth

Excellos Selected as Decentralized Manufacturing Unit to Support Galapagos' CAR-T Cell Therapy Clinical Study Close to Cancer Treatment Centers in the San Diego Area

Oct 1, 2024, 6:00 AM EDT - 1 year ago

Excellos Selected as Decentralized Manufacturing Unit to Support Galapagos' CAR-T Cell Therapy Clinical Study Close to Cancer Treatment Centers in the San Diego Area

Galapagos receives transparency notification from EcoR1 Capital

Sep 30, 2024, 4:01 PM EDT - 1 year ago

Galapagos receives transparency notification from EcoR1 Capital

Galapagos receives transparency notification from FMR LLC

Sep 3, 2024, 4:01 PM EDT - 1 year ago

Galapagos receives transparency notification from FMR LLC

Galapagos announces FDA clearance of IND application for Phase 1/2 ATALANTA-1 study of CD19 CAR-T, GLPG5101, in relapsed/refractory non-Hodgkin lymphoma

Aug 23, 2024, 1:00 AM EDT - 1 year ago

Galapagos announces FDA clearance of IND application for Phase 1/2 ATALANTA-1 study of CD19 CAR-T, GLPG5101, in relapsed/refractory non-Hodgkin lymphoma

BridGene Biosciences Expands Strategic Collaboration with Galapagos to Develop Selective Oral SMARCA2 PROTAC in Precision Oncology

Aug 1, 2024, 4:01 PM EDT - 2 years ago

BridGene Biosciences Expands Strategic Collaboration with Galapagos to Develop Selective Oral SMARCA2 PROTAC in Precision Oncology

Galapagos reports half-year 2024 financial results and provides second quarter business update

Aug 1, 2024, 4:01 PM EDT - 2 years ago

Galapagos reports half-year 2024 financial results and provides second quarter business update

Galapagos presents encouraging new data for CD19 CAR-T candidate GLPG5101 in non-Hodgkin lymphoma at EHA 2024

Jun 14, 2024, 4:01 PM EDT - 2 years ago

Galapagos presents encouraging new data for CD19 CAR-T candidate GLPG5101 in non-Hodgkin lymphoma at EHA 2024

Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively license Adaptimmune's TCR T-cell therapy candidate, uza-cel, in head & neck cancer and potential future solid tumor indications

May 30, 2024, 4:01 PM EDT - 2 years ago

Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively license Adaptimmune's TCR T-cell therapy candidate, uza-cel, in head & neck cancer and potential future solid tumor indications

Adaptimmune and Galapagos Sign Clinical Collaboration Agreement with an Option to Exclusively License Adaptimmune's TCR T-cell Therapy Candidate, uza-cel, in Head & Neck Cancer and Potential Future Solid Tumor Indications

May 30, 2024, 4:01 PM EDT - 2 years ago

Adaptimmune and Galapagos Sign Clinical Collaboration Agreement with an Option to Exclusively License Adaptimmune's TCR T-cell Therapy Candidate, uza-cel, in Head & Neck Cancer and Potential Future Solid Tumor Indications

PickAlpha
PickAlpha Jun. 5 at 11:58 AM
4/8: Gilead and Lakefront close Ouro Medicines acquisition; GILD pays $1.675B upfront plus up to $500M milestones to add OM336 (gamgertamig) to inflammation pipeline; Lakefront earns 20%–23% royalties. $GILD $LKFT $XBI $IBB
0 · Reply
The__short_squeezer
The__short_squeezer Jun. 2 at 10:46 AM
$BB $TSLA $LKFT $TOES.X $FLNC
0 · Reply
Newsfilter
Newsfilter Oct. 3 at 8:01 PM
$LKFT Galapagos receives positive CHMP opinion for Jyseleca® European label update based on testicular function safety data from MANTA/RAy studies https://newsfilter.io/a/d2cca2a430c7ba812fe008ac13e3ea5d
0 · Reply
DummiesNixGerafft
DummiesNixGerafft Oct. 3 at 5:15 PM
@PhaseHaiko @NoGainer1 @Bohrenn @Phase0ne @macht @oooOOO000OOOooo @Hailight @Franke093 @EuerHaiko_sollteKlarSein @EuerHaiko @Hainzelkind hc mega am liefern mit $MYOV , ngc depot wenigstens unch. $LKFT geht mal so richtig ab. Experten cash wird wohl auch knapp, die nächsten kostenpflichtigen Services schon in der mache. Safe.
2 · Reply
lulz
lulz Oct. 3 at 12:03 PM
$LKFT einen Rohrkrepierer nach dem andere im NBC
1 · Reply
Bohrenn
Bohrenn Oct. 3 at 10:32 AM
$LKFT Unfassbar, was im Scamdeals No Gainer Club geboten wird. Am 11.02.2021 Bewertung Risiko 1 von 5 auf Sicht von 18 Monaten und Zielrange ca. 92€. Heute, ca. 20 Monate später, haben wir mit dieser Club-Expertise ein Investment, dass circa 40% auf den EK verloren hat und das um circa 120% steigen muss, um in die Zielrange zu gelangen. Unfassbare Verluste nur im Scamdeals No Gainer Club. >> "Wir raten Dir, gleich mit einer soliden Startposition zu beginnen."
3 · Reply
MillionTrader_xy
MillionTrader_xy Oct. 3 at 9:47 AM
$LKFT noch nichts mehr gekauft, zuerst muss der Test des ATL bestehen. Bei größeren Dip nochmal 5-10% geh ich mit hohem Gewicht rein.
0 · Reply
oliveinvest
oliveinvest Sep. 28 at 7:17 PM
Generate income with protection from volatility🛡️. Call it cushion💸. Set your cushion to whatever percentage you like. See the cushion on this fixed return outcome on $LKFT Make a fixed 5.2% (17.5% annualized) GLPG can fall 20% thru exp before you start to lose. Buy 1 $30 put Sell 2 $35 puts Exp 1/20/23 Capital Req. $3801.98 👉🏼Click my profile link to see how its done.
0 · Reply
Newsfilter
Newsfilter Sep. 27 at 9:04 PM
$LKFT Form 6-K (report of foreign issuer [rules 13a-16 and 15d-16]) filed with the SEC https://newsfilter.io/a/6b944e2cccf431854f805e0ae4ae4d14
0 · Reply
fla
fla Sep. 27 at 8:03 PM
$LKFT [15s. delayed]: Issued Press Release on September 27, 16:01:00: Galapagos increases share capital through subscription right exercis https://s.flashalert.me/7LECoa
0 · Reply
Newsfilter
Newsfilter Sep. 27 at 8:01 PM
$LKFT Galapagos increases share capital through subscription right exercises https://newsfilter.io/a/631325e1bbaa4a7165dc4a0578775e28
0 · Reply
Dachshundtrader
Dachshundtrader Sep. 27 at 2:17 AM
$SPRO $ASMB $LKFT $SPRY
0 · Reply